Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Michael Behrens

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Virchows Archiv : an International Journal of Pathology|May 15, 2024
Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation studyDita Ulase, Hans-Michael Behrens, Christoph Röcken
Journal of Surgical Oncology|December 29, 2015
Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneityChristine Böger, Hans-Michael Behrens, Christoph Röcken
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|November 7, 2023
Exploration of the Tumour Biological Significance of PCLO in Gastric Cancer: Results from a Large Central European CohortMaximilian Bernhardt, Hans-Michael Behrens, Sandra Krüger, et al.
Journal of Cancer Research and Clinical Oncology|November 20, 2019
Sexual dimorphism in gastric cancer: tumor-associated neutrophils predict patient outcome only for womenFranziska Clausen, Hans-Michael Behrens, Sandra Krüger, et al.
Virchows Archiv : an International Journal of Pathology|April 15, 2026
JAK2 and NOTCH2 in gastric cancer - NOTCH2 is an independent prognosticator of poor patient outcomeSonja Jost, Hans-Michael Behrens, Thomas Becker, et al.
Annals of Diagnostic Pathology|October 13, 2014
Correlation between the expression of integrins in prostate cancer and clinical outcome in 1284 patientsKatharina Heß, Christine Böger, Hans-Michael Behrens, et al.
Oncoimmunology|May 17, 2017
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?Christine Böger, Hans-Michael Behrens, Sandra Krüger, et al.
Journal of Clinical Pathology|August 8, 2015
Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohortChristoph Röcken, Hans-Michael Behrens, Christine Böger, et al.
Scientific Reports|October 7, 2024
Myocardial inflammatory cells in cardiac amyloidosisPhilip Simon, Hans-Michael Behrens, Arnt Kristen, et al.
Plos One|February 15, 2022
FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohortThorben Schrumpf, Hans-Michael Behrens, Jochen Haag, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Virchows Archiv : an International Journal of Pathology|May 15, 2024
Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation studyDita Ulase, Hans-Michael Behrens, Christoph Röcken
Journal of Surgical Oncology|December 29, 2015
Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneityChristine Böger, Hans-Michael Behrens, Christoph Röcken
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|November 7, 2023
Exploration of the Tumour Biological Significance of PCLO in Gastric Cancer: Results from a Large Central European CohortMaximilian Bernhardt, Hans-Michael Behrens, Sandra Krüger, et al.
Journal of Cancer Research and Clinical Oncology|November 20, 2019
Sexual dimorphism in gastric cancer: tumor-associated neutrophils predict patient outcome only for womenFranziska Clausen, Hans-Michael Behrens, Sandra Krüger, et al.
Virchows Archiv : an International Journal of Pathology|April 15, 2026
JAK2 and NOTCH2 in gastric cancer - NOTCH2 is an independent prognosticator of poor patient outcomeSonja Jost, Hans-Michael Behrens, Thomas Becker, et al.
Annals of Diagnostic Pathology|October 13, 2014
Correlation between the expression of integrins in prostate cancer and clinical outcome in 1284 patientsKatharina Heß, Christine Böger, Hans-Michael Behrens, et al.
Oncoimmunology|May 17, 2017
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?Christine Böger, Hans-Michael Behrens, Sandra Krüger, et al.
Journal of Clinical Pathology|August 8, 2015
Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohortChristoph Röcken, Hans-Michael Behrens, Christine Böger, et al.
Scientific Reports|October 7, 2024
Myocardial inflammatory cells in cardiac amyloidosisPhilip Simon, Hans-Michael Behrens, Arnt Kristen, et al.
Plos One|February 15, 2022
FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohortThorben Schrumpf, Hans-Michael Behrens, Jochen Haag, et al.
Pageof 7